Private Equity

Paris reaffirms support for the Africa Adaptation Acceleration Program, a move signaling deeper diplomatic ties and a focus on African-led solutions.

Jasmine Hartin is vindicated as drug and assault charges are dismissed, raising questions about a 'weaponized' legal system in her ongoing public saga.

A U.S. firm enters Puerto Rico's embattled water market, promising advanced filtration for hospitals and hotels plagued by infrastructure woes.

A $1.1 billion joint venture in Kazakhstan is set to develop the world's largest tungsten reserve, challenging China's dominance in a critical mineral.

The Canadian restaurant giant defied a tough market in 2025, posting record sales and boosting investor payouts through strategic promotions and delivery.

As Gildan prepares to report its 2025 results, all eyes are on its strong activewear sales, the massive HanesBrands acquisition, and future guidance.

The pipeline giant's record $20B EBITDA is fueled by traditional energy, while it aggressively expands into renewables to power the digital economy.

In a major strategic pivot, Elkem will trade its Silicones division to Bluestar in exchange for its majority stake, reshaping the firm into a focused metals company.

A new 'Wuthering Heights' film arrives, but its true story may be its surprising link to the global phenomenon of the telenovela. How did it happen?

Magna beat Q4 expectations and raised its dividend, but a $591M tech impairment and looming Ford recall costs paint a complex picture for the auto giant.

To challenge TV giants, Philips is bypassing national ads for a hyper-local strategy, sponsoring the Razorbacks and Naturals to win hearts in Arkansas.

Japanese giant's all-cash acquisition of Tri Pointe Homes creates a top-5 U.S. builder, raising questions on affordability and market consolidation.

Hotel seven x seven Itoshima's 2026 relaunch unveils a 'Sunset Beach Club' with a new spa, elemental cuisine, and a blueprint for regional luxury.

As Guardian Pharmacy Services prepares for a key investor conference, it showcases strong growth while its industry faces a looming crisis. Can its model work?

After its lead anxiety drug failed a key trial, Vistagen turns to AI and a new menopause treatment to secure its future. Can the company recover?

Fermi America's plan to revive nuclear power for AI's energy needs with a massive Texas campus faces past industry failures and new legal scrutiny.

Appili Therapeutics lands a $40M deal to fight fungal threats, but with cash reserves low and loans due, can its science outpace its financial pressures?

FDA approval for new 6- and 24-count NARCAN packs aims to streamline distribution for first responders and public health groups on the front lines.

The firm behind a controversial drug-permissive sporting event is hitting Wall Street via a SPAC, challenging the ethics of global anti-doping standards.

Cohen & Co.-backed SPAC joins the hunt for a merger target, highlighting a renewed investor appetite for blank check companies in a maturing market.